KBI has worldwide collaborations with top pharmaceutical and biotech companies, as well as, academic institutions through the following platforms:
· Serviced-based Partnerships: We work with clients on exclusive service-based partnerships where we engage in confidential research according to Fee-for-Service (FFS) or Full-Time-Equivalent (FTE) type agreements. For the FFS model, contracts which are established based on a unit price per service are aligned with our clients’ well-defined milestones. Under the FTE model, KBI provides the clients with project teams and internal resources that are dedicated to their studies for a specified period of time at fixed rate per unit.
· Strategic Partnerships: KBI engages in preferred partnerships that provide expanded strategic services which warrant commitments to clients for animal exclusivity use or for the collaborative development of translational models across many therapeutic and research areas alongside “first right to use” agreements.
· Other Partnerships: KBI has exclusive co-marketing agreements with reputable global CROs to mutually advance a broad range of CRO services in China and in other parts of the world. We also have effective partnerships and external networks with medical or academic institutions and research laboratories that allow us valuable and timely access to a wide variety of extraordinary instrumentation and expert technical advice in order to expedite our fastidious in vitro and in vivo needs while providing efficient and cost-effective results.